Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus Erlotinib vs Sorafenib plus Placebo as First-Line Treatment for Hepatocellular Carcinoma
2008-006021-14Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib plus Erlotinib with Sorafenib plus Placebo (2 arms). Primary endpoints: Overall survival and Time to radiographic tumor progression. Started Apr 2009; status: completed.
02
Drugs
sorafeniberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-006021-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006021-14.